The study reveals how malaria parasites infect liver cells, a critical step in their lifecycle. The discovery provides new insights into the molecular details of malaria infection and has significant implications for developing new drugs and vaccines.
Researchers have created a comprehensive regulatory map of Mycobacterium tuberculosis, revealing how the bacterium adapts to changing conditions. This breakthrough provides unique insights into how TB survives in the host and how it can be tackled with new drug interventions.
Researchers mapped how critical molecules regulate inflammation during flu infection, discovering new targets for therapies. The study provided a holistic view of the host-pathogen interaction, revealing lipid mediators' dual role in controlling inflammation.
Researchers at two structural genomics centers determined 1,000 protein structures from infectious disease organisms, providing crucial insights into the deadliest diseases. The knowledge gained will aid in developing new interventions and therapeutic agents for drug-resistant strains of TB, MRSA, and other pathogens.
Researchers from Seattle BioMed, University of Copenhagen and University of Edinburgh report findings that could lead to new treatments for severe malaria. The studies identified specific parasite proteins associated with the disease, offering potential targets for drugs.
The Seattle Structural Genomics Center for Infectious Disease has solved over 375 protein structures, providing a blueprint for fighting infectious disease. The center's work may lead to new drug therapies urgently needed to prevent outbreaks of multi-drug resistant and XDR strains of TB.
Vaccine development for 'big three' diseases is being accelerated by new approaches like systems biology and structure-based antigen design. Systems biology enables the capture of massive biological data to predict vaccine behavior.
Research in African monkeys reveals that CD4 T-cell depletion is one part of a complex scenario leading to AIDS. Studies suggest that immune function can be preserved despite significant loss of mucosal CD4 T-cells.
The genome sequences of Trypanosoma brucei, Trypanosoma cruzi, and Leishmania major have been completed, providing a blueprint for developing new drugs. The shared core of genes among the three parasites offers potential targets for a class of drugs that can target all three diseases.